That is why down-regulation of MCL1 in FBW7-deficient T-ALL cells is expected to overcome the therapeutic resistance to the BH3 mimetic ABT-737, which is a pan-inhibitor of the Bcl-2 family of anti-apoptotic proteins including BCL2, BCLXL, and BCLW. Here, MCL1 is linked to acute lymphoblastic leukemia.